Base de dados : MEDLINE
Pesquisa : D03.383.606.515 [Categoria DeCS]
Referências encontradas : 1126 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 113 ir para página                         

  1 / 1126 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28609444
[Au] Autor:Murata Y; Sugi T; Weiss LM; Kato K
[Ad] Endereço:National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido, Japan.
[Ti] Título:Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites.
[So] Source:PLoS One;12(6):e0178203, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Drug treatment for toxoplasmosis is problematic, because current drugs cannot eradicate latent infection with Toxoplasma gondii and can cause bone marrow toxicity. Because latent infection remains after treatment, relapse of infection is a problem in both infections in immunocompromised patients and in congenitally infected patients. To identify lead compounds for novel drugs against Toxoplasma gondii, we screened a chemical compound library for anti-Toxoplasma activity, host cell cytotoxicity, and effect on bradyzoites. Of 878 compounds screened, 83 demonstrated >90% parasite growth inhibition. After excluding compounds that affected host cell viability, we further characterized two compounds, tanshinone IIA and hydroxyzine, which had IC50 values for parasite growth of 2.5 µM and 1.0 µM, respectively, and had no effect on host cell viability at 25 µM. Both tanshinone IIA and hydroxyzine inhibited parasite replication after invasion and both reduced the number of in vitro-induced bradyzoites, whereas, pyrimethamine, the current therapy, had no effect on bradyzoites. Both tanshinone IIA and hydroxyzine are potent lead compounds for further medicinal chemistry. The method presented for evaluating compounds for bradyzoite efficacy represents a new approach to the development of anti-Toxoplasma drugs to eliminate latency and treat acute infection.
[Mh] Termos MeSH primário: Antiprotozoários/farmacologia
Toxoplasma/efeitos dos fármacos
Toxoplasmose Animal/tratamento farmacológico
Toxoplasmose/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antiprotozoários/química
Antiprotozoários/isolamento & purificação
Linhagem Celular
Cercopithecus aethiops
Diterpenos Abietanos/química
Diterpenos Abietanos/farmacologia
Interações Hospedeiro-Parasita/efeitos dos fármacos
Seres Humanos
Hidroxizina/química
Hidroxizina/farmacologia
Estrutura Molecular
Pirimetamina/química
Pirimetamina/farmacologia
Toxoplasma/fisiologia
Toxoplasmose/parasitologia
Toxoplasmose Animal/parasitologia
Células Vero
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Diterpenes, Abietane); 03UUH3J385 (tanshinone); 30S50YM8OG (Hydroxyzine); Z3614QOX8W (Pyrimethamine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170614
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0178203


  2 / 1126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28058761
[Au] Autor:Kanthiah S; Kannappan V
[Ad] Endereço:Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Annamalai Nagar, Tamil Nadu, India.
[Ti] Título:D-Optimal mixture design optimization of an HPLC method for simultaneous determination of commonly used antihistaminic parent molecules and their active metabolites in human serum and urine.
[So] Source:Biomed Chromatogr;31(8), 2017 Aug.
[Is] ISSN:1099-0801
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study describes a specific, precise, sensitive and accurate method for simultaneous determination of hydroxyzine, loratadine, terfenadine, rupatadine and their main active metabolites cetirizine, desloratadine and fexofenadine, in serum and urine using meclizine as an internal standard. Solid-phase extraction method for sample clean-up and preconcentration of analytes was carried out using Phenomenex Strata-X-C and Strata X polymeric cartridges. Chromatographic analysis was performed on a Phenomenex cyano (150 × 4.6 mm i.d., 5 µm) analytical column. A D-optimal mixture design methodology was used to evaluate the effect of changes in mobile phase compositions on dependent variables and optimization of the response of interest. The mixture design experiments were performed and results were analyzed. The region of ideal mobile phase composition consisting of acetonitrile-methanol-ammonium acetate buffer (40 mm; pH 3.8 adjusted with acetic acid): 18:36:46% v/v/v was identified by a graphical optimization technique using an overlay plot. While using this optimized condition all analytes were baseline resolved in <10 min. Solvent mixtures were delivered at 1.5 mL/min flow rate and analytes peaks were detected at 222 nm. The proposed bioanalytical method was validated according to US Food and Drug Administration guidelines. The proposed method was sensitive with detection limits of 0.06-0.15 µg/mL in serum and urine samples. Relative standard deviation for inter- and intra-day precision data was found to be <7%. The proposed method may find application in the determination of selected antihistaminic drugs in biological fluids.
[Mh] Termos MeSH primário: Antialérgicos/sangue
Antialérgicos/urina
Cromatografia Líquida de Alta Pressão/métodos
Antagonistas dos Receptores Histamínicos H1/sangue
Antagonistas dos Receptores Histamínicos H1/urina
[Mh] Termos MeSH secundário: Antialérgicos/metabolismo
Ciproeptadina/análogos & derivados
Ciproeptadina/sangue
Ciproeptadina/metabolismo
Ciproeptadina/urina
Antagonistas dos Receptores Histamínicos H1/metabolismo
Seres Humanos
Hidroxizina/sangue
Hidroxizina/metabolismo
Hidroxizina/urina
Limite de Detecção
Loratadina/sangue
Loratadina/metabolismo
Loratadina/urina
Extração em Fase Sólida/métodos
Terfenadina/sangue
Terfenadina/metabolismo
Terfenadina/urina
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Histamine H1 Antagonists); 2AE8M83G3E (rupatadine); 2YHB6175DO (Cyproheptadine); 30S50YM8OG (Hydroxyzine); 7AJO3BO7QN (Loratadine); 7BA5G9Y06Q (Terfenadine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE
[do] DOI:10.1002/bmc.3932


  3 / 1126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27712113
[Au] Autor:Erlendson MJ; D'Arcy N; Encisco EM; Yu JJ; Rincon-Cruz L; Peltz G; Clark JD; Chu LF
[Ad] Endereço:a Department of Anesthesia , Stanford University School of Medicine , Stanford , CA , USA.
[Ti] Título:Palonosetron and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study.
[So] Source:Am J Drug Alcohol Abuse;43(1):78-86, 2017 Jan.
[Is] ISSN:1097-9891
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Treatments for reducing opioid withdrawal are limited and prone to problematic side effects. Laboratory studies, clinical observations, and limited human trial data suggest 5-HT3-receptor antagonists and antihistamines may be effective. OBJECTIVES: This double-blind, crossover, placebo-controlled study employing an acute physical dependence model evaluated whether (i) treatment with a 5-HT3-receptor antagonist (palonosetron) would reduce opioid withdrawal symptoms, and (ii) co-administration of an antihistamine (hydroxyzine) would enhance any treatment effect. METHODS: At timepoint T = 0, healthy (non-opioid dependent, non-substance abuser) male volunteers (N = 10) were pre-treated with either a) placebo, b) palonosetron IV (0.75 mg), or c) palonosetron IV (0.75 mg) and hydroxyzine PO (100 mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10 mg/70kg). At T = 165, 10 mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15. RESULTS: Comparison of average baseline OOWS scores with OOWS scores obtained 15 minutes after naloxone was significant (p = 0.0001). Scores from 15 minutes post-naloxone infusion showed significant differences in OOWS scores between treatment groups: placebo, 3.7 ± 2.4; palonosetron, 1.5 ± 0.97; and palonosetron with hydroxyzine, 0.2 ± 0.1333. CONCLUSIONS: Pretreatment with palonosetron significantly reduced many signs of experimentally-induced opioid withdrawal. Co-administration with hydroxyzine further reduced opioid withdrawal severity. These results suggest that 5-HT3 receptor antagonists, alone or in combination with an antihistamine, may be useful in the treatment of opioid withdrawal.
[Mh] Termos MeSH primário: Hidroxizina/uso terapêutico
Isoquinolinas/uso terapêutico
Quinuclidinas/uso terapêutico
Síndrome de Abstinência a Substâncias/tratamento farmacológico
[Mh] Termos MeSH secundário: Estudos Cross-Over
Método Duplo-Cego
Sinergismo Farmacológico
Voluntários Saudáveis
Seres Humanos
Masculino
Morfina/efeitos adversos
Morfina/antagonistas & inibidores
Naloxona/farmacologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Isoquinolines); 0 (Quinuclidines); 30S50YM8OG (Hydroxyzine); 36B82AMQ7N (Naloxone); 5D06587D6R (palonosetron); 76I7G6D29C (Morphine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161008
[St] Status:MEDLINE
[do] DOI:10.1080/00952990.2016.1210614


  4 / 1126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26755506
[Au] Autor:Dirani M; Nasreddine W; Melhem J; Arabi M; Beydoun A
[Ad] Endereço:Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
[Ti] Título:Efficacy of the Sequential Administration of Melatonin, Hydroxyzine, and Chloral Hydrate for Recording Sleep EEGs in Children.
[So] Source:Clin EEG Neurosci;48(1):41-47, 2017 Jan.
[Is] ISSN:2169-5202
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Sedation of children for electroencephalography (EEG) recordings is often required. Chloral hydrate (CH) requires medical clearance and continuous monitoring. To try to reduce personnel and time resources associated with CH administration, a new sedation policy was formulated. This study included all children who underwent an EEG during a consecutive 3-month period following the implementation of the new sedation policy, which consists of the sequential administration of melatonin, hydroxyzine (if needed), and CH (if needed). The comparator group included all children with a recorded EEG during a consecutive 3-month period when the sedation policy consisted of the sole administration of CH. A total of 803 children with a mean age of 7.9 years (SD = 5.1, range = 0.5-17.7 years) were included. Sleep EEG recordings were obtained in 364 of 385 children (94.6%) using the old sedation policy and in 409 of 418 children (97.9%) using the new one. With the new sedation policy, the percentage of children requiring CH dropped from 37.1% to 6.7% (P < .001). Time to sleep onset and duration of sleep were not significantly different between the 2 policies. The new sedation policy was very well tolerated. The new sedation policy is very safe, is highly efficacious in obtaining sleep EEG recordings, and will result in substantial saving of time and personnel resources.
[Mh] Termos MeSH primário: Hidrato de Cloral/administração & dosagem
Eletroencefalografia/efeitos dos fármacos
Hidroxizina/administração & dosagem
Melatonina/administração & dosagem
Sono/efeitos dos fármacos
Sono/fisiologia
[Mh] Termos MeSH secundário: Depressores do Sistema Nervoso Central
Criança
Pré-Escolar
Sedação Consciente/métodos
Esquema de Medicação
Quimioterapia Combinada/métodos
Eletroencefalografia/métodos
Feminino
Seres Humanos
Hipnóticos e Sedativos
Lactente
Masculino
Polissonografia/métodos
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Resultado do Tratamento
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Depressants); 0 (Hypnotics and Sedatives); 30S50YM8OG (Hydroxyzine); 418M5916WG (Chloral Hydrate); JL5DK93RCL (Melatonin)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170227
[Lr] Data última revisão:
170227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160113
[St] Status:MEDLINE


  5 / 1126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27968973
[Au] Autor:Roynard P; Castel C; Lebain P; Roupie É; Saint-Lorant G
[Ad] Endereço:Pharmacie centrale, CHU de Caen, Avenue de la Côte de Nacre, 14033 Caen Cedex, France.
[Ti] Título:Violences et thérapeutiques 1/2..
[So] Source:Rev Infirm;65(225):45-46, 2016 Nov.
[Is] ISSN:1293-8505
[Cp] País de publicação:France
[La] Idioma:fre
[Mh] Termos MeSH primário: Antipruriginosos/efeitos adversos
Hidroxizina/efeitos adversos
Transtornos Mentais/induzido quimicamente
Violência
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipruritics); 30S50YM8OG (Hydroxyzine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170406
[Lr] Data última revisão:
170406
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:161215
[St] Status:MEDLINE


  6 / 1126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
[PMID]:27899067
[Au] Autor:Hammami MM; Hammami S; Al-Swayeh R; Al-Gaai E; Farah FA; De Padua SJ
[Ad] Endereço:Department of Clinical Studies and Empirical Ethics, King Faisal Specialist Hospital and Research Center, P O Box # 3354 (MBC 03), Riyadh, 11211, Saudi Arabia. Muhammad@kfshrc.edu.sa.
[Ti] Título:Drug*placebo interaction effect may bias clinical trials interpretation: hybrid balanced placebo and randomized placebo-controlled design.
[So] Source:BMC Med Res Methodol;16(1):166, 2016 Nov 29.
[Is] ISSN:1471-2288
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Conventional randomized placebo-controlled study design assumes the absence of drug*placebo interaction. We hypothesized the presence of such an interaction and that conventionally estimated drug effect might be biased. The objectives of the study were to determine the drug*placebo interaction effect (main) and compare conventionally estimated and interaction model-estimated drug effects (secondary). METHODS: We used a hybrid of balanced placebo and randomized placebo-controlled designs. Four hundred eighty healthy volunteers were randomized to three groups. The first received hydroxyzine (25 mg) described as hydroxyzine or placebo, the second received placebo described as hydroxyzine or placebo, and the third received hydroxyzine and placebo described as unknown; each in a randomized crossover design. Seven participants failed to crossover. Group assignment was concealed from participants and study coordinators. Coordinators were blinded to group and intervention assignment. Participants and coordinators were deceived as to study objectives. Main outcomes were mean area-under-the-curve of drowsiness (therapeutic outcome) and mouth-dryness (adverse outcome), self-reported on 100 mm visual analog scale over 7 h. Drug, placebo, placebo + interaction, and total effects were estimated using analysis of covariance by comparing received hydroxyzine/told placebo to received placebo/told placebo, received placebo/told hydroxyzine to received placebo/told placebo, received hydroxyzine/told hydroxyzine to received hydroxyzine/told placebo, and received hydroxyzine/told hydroxyzine to received placebo/told placebo, respectively. Drug effect was also conventionally estimated in the third group. RESULTS: Mean (SD) age was 31.4 (6.6) years, 65% were males. There was significant difference between placebo + interaction effect and placebo effect for both drowsiness and mouth-dryness with a mean difference (95% confidence interval) of 35.1 (5.6 to 64.6) and 23.8 (2.4 to 45.2) mm*hr, respectively. Total effect was larger than the sum of drug and placebo effects for drowsiness (139.7 (109.8 to 169.6) vs. 99.1 (68.2 to 130.0) mm*hr) and mouth-dryness (63.6 (41.1 to 86.1) vs. 34.7 (11.1 to 58.4) mm*hr). Conventionally estimated drug effect was larger than interaction model-estimated drug effect for drowsiness (69.2 (45.5 to 92.8) vs. (58.3 (31.6 to 85.0) mm*hr) and mouth-dryness (19.9 (5.3 to 34.5) vs. 9.5 (-9.2 to 28.1) mm*hr). CONCLUSIONS: There is significant and important drug*placebo interaction effect that may bias conventionally estimated drug effect. TRIAL REGISTRATION: ClinicalTrial.gov identifier: NCT01501591 (registered December 25, 2011).
[Mh] Termos MeSH primário: Interações Medicamentosas
Hidroxizina/administração & dosagem
Efeito Placebo
Placebos/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Viés
Ensaios Clínicos como Assunto/métodos
Ensaios Clínicos como Assunto/normas
Ensaios Clínicos como Assunto/estatística & dados numéricos
Estudos Cross-Over
Método Duplo-Cego
Feminino
Antagonistas dos Receptores Histamínicos H1/administração & dosagem
Seres Humanos
Masculino
Avaliação de Resultados (Cuidados de Saúde)/métodos
Avaliação de Resultados (Cuidados de Saúde)/normas
Avaliação de Resultados (Cuidados de Saúde)/estatística & dados numéricos
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Histamine H1 Antagonists); 0 (Placebos); 30S50YM8OG (Hydroxyzine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161201
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  7 / 1126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27436188
[Au] Autor:Bartoli F; Bruni C; Cometi L; Blagojevic J; Fiori G; Tofani L; Galluccio F; Furst DE; Matucci Cerinic M
[Ad] Endereço:Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Villa Monna Tessa, Viale Pieraccini 18, 50134, Florence, Italy. francesca.bartoli19@gmail.com.
[Ti] Título:Premedication prevents infusion reactions and improves retention rate during infliximab treatment.
[So] Source:Clin Rheumatol;35(11):2841-2845, 2016 Nov.
[Is] ISSN:1434-9949
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Infliximab (IFX) is an anti-tumor necrosis factor-alpha antibody used to treat inflammatory joint diseases. Infusion reactions (IR) can occur during and after intravenous administration and often require discontinuation of IFX therapy. This retrospective study aimed at evaluating the incidence of IR in patients with joint inflammatory diseases receiving IFX with and without premedication. Clinical charts of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients receiving IFX from January 2002 to December 2014 were reviewed. Patients receiving only one premedication protocol over time were enrolled and clustered based on the type of premedication as follows: group 1 received no premedication; group 2 received paracetamol, esomeprazole, hydrocortisone, and chlorpheniramine maleate; group 3 received paracetamol, hydoxyzine, ranitidine, and 6-methylprednisolone. Adverse events were recorded during the infusion, in the following hours and at control visits. The charts of 105 patients treated with IFX were selected. IR were observed in 23/51 patients of group 1, in 7/35 patients of group 2, and none of 19 patients in group 3. IR incidence was significantly lower in the second (p = 0.021) and third (p < 0.001) compared to the first group. The incidence of IR was significantly lower in group 3 than group 2 (p < 0.043). Moreover, patients in group 1 had a relative risk of developing an IR 2.5 times higher than group 2. In our experience, the use of premedication significantly reduced the number of IR to IFX. In particular, the combination of paracetamol, hydroxyzine, 6-methylprednisolone and ranitidine was more efficacious than paracetamol, esomeprazole, hydrocortisone, and chlorpheniramine maleate combination protocol.
[Mh] Termos MeSH primário: Antirreumáticos/efeitos adversos
Artrite Reumatoide/tratamento farmacológico
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle
Infliximab/efeitos adversos
Pré-Medicação
[Mh] Termos MeSH secundário: Acetaminofen/uso terapêutico
Adulto
Idoso
Antirreumáticos/uso terapêutico
Artrite Psoriásica/tratamento farmacológico
Clorfeniramina/uso terapêutico
Quimioterapia Combinada
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/etiologia
Esomeprazol/uso terapêutico
Feminino
Seres Humanos
Hidrocortisona/uso terapêutico
Hidroxizina/uso terapêutico
Infliximab/uso terapêutico
Infusões Intravenosas/efeitos adversos
Masculino
Metilprednisolona/uso terapêutico
Meia-Idade
Ranitidina/uso terapêutico
Estudos Retrospectivos
Espondilite Anquilosante/tratamento farmacológico
Resultado do Tratamento
Fator de Necrose Tumoral alfa/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antirheumatic Agents); 0 (Tumor Necrosis Factor-alpha); 30S50YM8OG (Hydroxyzine); 362O9ITL9D (Acetaminophen); 3U6IO1965U (Chlorpheniramine); 884KT10YB7 (Ranitidine); B72HH48FLU (Infliximab); N3PA6559FT (Esomeprazole); WI4X0X7BPJ (Hydrocortisone); X4W7ZR7023 (Methylprednisolone)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160721
[St] Status:MEDLINE


  8 / 1126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27370062
[Au] Autor:Sevi Tok ES; Arkar H; Bildik T
[Ti] Título:[The Effectiveness of Cognitive Behavioral Therapy, Medication, or Combined Treatment For Child Hood Anxiety Disorders].
[Ti] Título:Çocukluk Çagi Kaygi Bozukluklarinda Bilissel Davranisçi Terapi, Ilaç Tedavisi ve Kombine Tedavinin Etkililiginin Karsilastirilmasi..
[So] Source:Turk Psikiyatri Derg;27(2):0, 2016.
[Is] ISSN:1300-2163
[Cp] País de publicação:Turkey
[La] Idioma:tur
[Ab] Resumo:OBJECTIVE: The aims of this study were to evaluate the effectiveness of the Fear Hunter cognitive behavioral therapy program, which was developed for the treatment of childhood anxiety disorders, and to compare its effectiveness with standard medication treatment. METHOD: A total of 46 participants (aged 8 to 12) that applied to the Ege University, Faculty of Medicine, Child and Adolescent Psychiatry clinic and had a diagnosis of anxiety disorder were recruited for the study. The participants were randomly assigned to cognitive behavioral therapy (CBT), standard drug treatment (ST), or combined treatment (CBT+ ST) groups according to the order of application. Subjects were evaluated using pretest, posttest and 3 months follow-up measurements. The participants were assessed by the researcher using The Screen for Child Anxiety Related Emotional Disorders (SCARED), The Children's Negative Cognitive Errors Questionnaire (CNCEQ), Health Related Quality of Life in Children (Kid-KINDL), and Children's Depression Inventory (CDI). RESULTS: The results of repeated measures ANOVA showed that, although general anxiety scores of all treatment conditions significantly decreased at posttest and follow up, a combination of two therapies (CBT+ST) had a significantly superior response rate. Moreover, all treatment conditions including CBT (CBT+ST and CBT) were superior to ST in terms of negative cognitive errors, quality of life, and depression. CONCLUSION: It is thought that The Fear Hunter Therapy Program is an effective treatment technique because; it provides significant improvement in the primary and secondary symptoms (e.g. quality of life, depression, negative automatic thoughts) of childhood anxiety disorders.
[Mh] Termos MeSH primário: Ansiolíticos/uso terapêutico
Transtornos de Ansiedade/terapia
Terapia Cognitiva
[Mh] Termos MeSH secundário: Transtornos de Ansiedade/tratamento farmacológico
Transtornos de Ansiedade/psicologia
Criança
Terapia Combinada
Feminino
Fluoxetina/uso terapêutico
Seres Humanos
Hidroxizina/uso terapêutico
Masculino
Escalas de Graduação Psiquiátrica
Sertralina/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Anxiety Agents); 01K63SUP8D (Fluoxetine); 30S50YM8OG (Hydroxyzine); QUC7NX6WMB (Sertraline)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170327
[Lr] Data última revisão:
170327
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160703
[St] Status:MEDLINE


  9 / 1126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27252070
[Au] Autor:Kameda K; Watarai K; Takahashi K; Shoko T; Koinuma M; Ikushima G
[Ad] Endereço:Depertment of Pharmacy, Matsudo City Hospital.
[Ti] Título:Pharmaceutical Approach for the Diagnosis and Treatment of Malignant Syndrome: A Case Study.
[So] Source:Yakugaku Zasshi;136(6):925-9, 2016.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Since 2012, Matsudo City Hospital has increased the number of pharmacists stationed in the ward on weekday mornings at the emergency care center, the intensive care unit (ICU) and the high care unit (HCU). Multidisciplinary joint meetings and joint conferences are conducted in the emergency care center, and patient and drug information is shared. A 20-year-old man was transferred to our hospital after a traffic accident. He was diagnosed with subarachnoid hemorrhage and brain contusion. He exhibited violent movement and intense restlessness. He was sedated with a continuous intravenous infusion of 5 mg/h midazolam and 20 µg/h fentanyl, with intubation. Propofol was also used intermittently. The midazolam infusion was concluded on day 5 of hospitalization. However, his restlessness recurred so an intravenous drip infusion of 150 mg/h haloperidol was administered. On the 7th day, he developed a high-grade fever, muscle rigidity, perspiration, and leukocytosis, and malignant syndrome or malignant hyperthermia was suspected. For malignant syndrome treatment, he received an intravenous drip infusion of 60 mg dantrolene, followed by the combined oral administration of 100 mg/d dantrolene and 7.5 mg/d bromocriptine. Considering various pharmacological effects, we selected an intravenous drip infusion of 25 mg hydroxyzine hydrochloride as the drug to alleviate restlessness. The patient's course continued without recurrence of malignant syndrome; his symptoms improved because of pharmaceutical care with an awareness of patient benefits through clinical and laboratory findings, consultation with the attending physician, presentation of information on causative and therapeutic drugs, and coordinated planning of a prescription design.
[Mh] Termos MeSH primário: Antipsicóticos/efeitos adversos
Bromocriptina/administração & dosagem
Dantroleno/administração & dosagem
Haloperidol/efeitos adversos
Hidroxizina/administração & dosagem
Comunicação Interdisciplinar
Síndrome Maligna Neuroléptica/diagnóstico
Síndrome Maligna Neuroléptica/tratamento farmacológico
Equipe de Assistência ao Paciente
Assistência Farmacêutica
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Quimioterapia Combinada
Seres Humanos
Infusões Intravenosas
Masculino
Síndrome Maligna Neuroléptica/etiologia
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 30S50YM8OG (Hydroxyzine); 3A64E3G5ZO (Bromocriptine); F64QU97QCR (Dantrolene); J6292F8L3D (Haloperidol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160603
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.15-00218


  10 / 1126 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27186625
[Ti] Título:Drugs to avoid in pregnant women with allergies.
[So] Source:Prescrire Int;25(170):103, 2016 Apr.
[Is] ISSN:1167-7422
[Cp] País de publicação:France
[La] Idioma:eng
[Mh] Termos MeSH primário: Anormalidades Induzidas por Medicamentos/etiologia
Arritmias Cardíacas/induzido quimicamente
Antagonistas dos Receptores Histamínicos H1/efeitos adversos
Hidroxizina/efeitos adversos
Hipotensão/induzido quimicamente
Fenotiazinas/efeitos adversos
Complicações Cardiovasculares na Gravidez/induzido quimicamente
Complicações na Gravidez/tratamento farmacológico
Rinite Alérgica/tratamento farmacológico
[Mh] Termos MeSH secundário: Doenças dos Gânglios da Base/induzido quimicamente
Feminino
Seres Humanos
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Histamine H1 Antagonists); 0 (Phenothiazines); 30S50YM8OG (Hydroxyzine)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:160517
[Lr] Data última revisão:
160517
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:160518
[St] Status:MEDLINE



página 1 de 113 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde